Thursday 31 March 2016, Amsterdam
The report, now available on ASDReports, recognizes the following companies as the key players in the Global Immunotherapy Drugs Market: AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Johnson & Johnson Private Ltd., and Merck & Co. Inc.
Other Prominent Vendors in the market are: AB Science, Ablynx, Acorda Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys Inc., Agenus Inc., Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma, Antigen Express, Argos Therapeutics Inc., Astellas Pharma, AstraZeneca, AVAX Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical, Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus BioSciences, CTI BioPharma, CureVac, Cytos Biotachnology, Daiichi Sankyo, Eisai, Eli Lilly, Fortress Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune, Gradalis, Heat Biologics, Hospira, Idera, Immatics, ImmunoCellular Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals, Oncothyreon, Oncovir Inc., Opexa Therapeutics Inc., Oxford BioMedica, Pfizer, Prima BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz, Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech, Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, and XBiotech.
Commenting on the report, an analyst said: “The rising prevalence of cancer and autoimmune diseases has led to innovations and technological advancements, which have helped develop immunotherapy drugs that are more effective than available drugs.”
According to the report, the rising prevalence of cancer and autoimmune diseases has led to innovations and technological advancements, which have helped develop immunotherapy drugs that are more effective than available drugs.
Further, the report states that the patent expiries of branded drugs may hamper the market as this results in the entry of biosimilars, which are less expensive.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.